Literature DB >> 24548662

Systemic inflammation is related to coronary microvascular dysfunction in obese patients without obstructive coronary disease.

F Tona1, R Serra2, L Di Ascenzo1, E Osto1, A Scarda2, R Fabris2, R Montisci3, G Famoso1, S Tellatin1, M Foletto4, A Giovagnoni5, S Iliceto1, R Vettor6.   

Abstract

BACKGROUND AND AIMS: Obesity, systemic inflammation and changes in the heart functions are associated with increased cardiovascular risk. This study aimed to investigate coronary microvascular dysfunction as an early marker of atherosclerosis in obese patients without any evidence of cardiovascular disease. METHODS AND
RESULTS: 86 obese subjects (aged 44 ± 12 years, body mass index (BMI) 41 ± 8 kg m(-2)), without evidence of heart disease, and 48 lean controls were studied using transthoracic Doppler echocardiography for detecting coronary flow reserve (CFR). A value of CFR ≤ 2.5 was considered abnormal. We measured interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α) and adiponectin in all patients. Patients with abnormal CFR underwent coronary multislice computed tomography (MSCT) in order to exclude an epicardial stenosis. CFR in obese subjects was lower than in lean subjects (3.2 ± 0.8 vs. 3.7 ± 0.7, p = 0.02) and was abnormal in 27 (31%) obese patients and in one (2%) control (p < 0.0001). All subjects with abnormal CFR showed no coronary stenosis at MSCT. At multivariable analysis, IL-6 and TNF-α were the only determinants of CFR (p < 0.02 and p < 0.02, respectively). At multivariable logistic regression analysis, IL-6 and TNF-α were the only determinants of CFR ≤ 2.5 (p < 0.03 and p < 0.03, respectively).
CONCLUSIONS: CFR is often reduced in obese subjects without clinical evidence of heart disease, suggesting a coronary microvascular impairment. This microvascular dysfunction seems to be related to a chronic inflammation mediated by adipocytokines. Our findings may explain the increased cardiovascular risk in obesity, independently of BMI.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Coronary flow reserve; Inflammation; Microvascular dysfunction; Obesity; Prevention

Mesh:

Substances:

Year:  2013        PMID: 24548662     DOI: 10.1016/j.numecd.2013.09.021

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  26 in total

1.  Coronary Microvascular Dysfunction and Cardiovascular Risk in Obese Patients.

Authors:  Navkaranbir S Bajaj; Michael T Osborne; Ankur Gupta; Ali Tavakkoli; Paco E Bravo; Tomas Vita; Courtney F Bibbo; Jon Hainer; Sharmila Dorbala; Ron Blankstein; Deepak L Bhatt; Marcelo F Di Carli; Viviany R Taqueti
Journal:  J Am Coll Cardiol       Date:  2018-08-14       Impact factor: 24.094

Review 2.  Women with Stable Angina Pectoris and No Obstructive Coronary Artery Disease: Closer to a Diagnosis.

Authors:  Marie Mide Michelsen; Naja Dam Mygind; Daria Frestad; Eva Prescott
Journal:  Eur Cardiol       Date:  2017-08

3.  Myocardial perfusion in patients with non-ischaemic systolic heart failure and type 2 diabetes: a cross-sectional study using Rubidium-82 PET/CT.

Authors:  Christina Byrne; Philip Hasbak; Andreas Kjaer; Jens Jakob Thune; Lars Køber
Journal:  Int J Cardiovasc Imaging       Date:  2017-12-28       Impact factor: 2.357

Review 4.  Endothelial-cell-mediated mechanism of coronary microvascular dysfunction leading to heart failure with preserved ejection fraction.

Authors:  Yong Wang; Juan Zhang; Zhen Wang; Cheng Wang; Dufang Ma
Journal:  Heart Fail Rev       Date:  2022-03-09       Impact factor: 4.214

Review 5.  Coronary Microvascular Dysfunction: A Practical Approach to Diagnosis and Management.

Authors:  Daria Frestad Bechsgaard; Eva Prescott
Journal:  Curr Atheroscler Rep       Date:  2021-07-16       Impact factor: 5.113

6.  Small whole heart volume predicts cardiovascular events in patients with stable chest pain: insights from the PROMISE trial.

Authors:  Borek Foldyna; Roman Zeleznik; Parastou Eslami; Thomas Mayrhofer; Jan-Erik Scholtz; Maros Ferencik; Daniel O Bittner; Nandini M Meyersohn; Stefan B Puchner; Hamed Emami; Patricia A Pellikka; Hugo J W L Aerts; Pamela S Douglas; Michael T Lu; Udo Hoffmann
Journal:  Eur Radiol       Date:  2021-01-26       Impact factor: 7.034

7.  Activation of κ-opioid receptor by U50,488H improves vascular dysfunction in streptozotocin-induced diabetic rats.

Authors:  Xuan Zhou; Dongjuan Wang; Yuyang Zhang; Jinxia Zhang; Dingcheng Xiang; Haichang Wang
Journal:  BMC Endocr Disord       Date:  2015-02-28       Impact factor: 2.763

8.  Renal function and coronary microvascular dysfunction in women with symptoms/signs of ischemia.

Authors:  Rajesh Mohandas; Mark S Segal; Tianyao Huo; Eileen M Handberg; John W Petersen; B Delia Johnson; George Sopko; C Noel Bairey Merz; Carl J Pepine
Journal:  PLoS One       Date:  2015-05-07       Impact factor: 3.240

9.  Coronary microvascular function is independently associated with left ventricular filling pressure in patients with type 2 diabetes mellitus.

Authors:  Takayuki Kawata; Masao Daimon; Sakiko Miyazaki; Ryoko Ichikawa; Masaki Maruyama; Shuo-Ju Chiang; Chiharu Ito; Fumihiko Sato; Hirotaka Watada; Hiroyuki Daida
Journal:  Cardiovasc Diabetol       Date:  2015-08-05       Impact factor: 9.951

10.  Human coronary microvascular contractile dysfunction associates with viable synthetic smooth muscle cells.

Authors:  Kim A Dora; Lyudmyla Borysova; Xi Ye; Chloe Powell; Timea Z Beleznai; Christopher P Stanley; Vito D Bruno; Tobias Starborg; Errin Johnson; Anna Pielach; Michael Taggart; Nicola Smart; Raimondo Ascione
Journal:  Cardiovasc Res       Date:  2022-06-29       Impact factor: 13.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.